IL32 and cancer: Mechanistically, it is shown that YY1 signaling upregulates IL32 secretion in PCs, subsequently activating the β5‐integrin‐Src‐Akt pathway in EGFR‐mutated cancer cells, contributing to their TKI sensitivity.